Orgenesis Inc. Completes Acquisition
Ticker: ORGS · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1460602
| Field | Detail |
|---|---|
| Company | Orgenesis INC. (ORGS) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $11,000,000, $10,767,298, $3.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, definitive-agreement
TL;DR
Orgenesis just bought something, details TBD.
AI Summary
Orgenesis Inc. announced on July 10, 2024, the completion of an acquisition. The company entered into a material definitive agreement related to this transaction. Specific financial details and the name of the acquired entity were not disclosed in this initial filing.
Why It Matters
This filing indicates a significant strategic move by Orgenesis Inc. through an acquisition, which could impact its future growth and market position.
Risk Assessment
Risk Level: medium — Acquisitions inherently carry risks related to integration, valuation, and market reception, which are not fully detailed in this initial report.
Key Players & Entities
- Orgenesis Inc. (company) — Registrant
- July 10, 2024 (date) — Date of earliest event reported
FAQ
What specific assets or business did Orgenesis Inc. acquire?
The filing does not specify the exact assets or business acquired, only that a material definitive agreement was entered into and the acquisition was completed.
What was the financial consideration for this acquisition?
The filing does not disclose the dollar amount or any financial terms of the acquisition.
Who is the counterparty in this acquisition agreement?
The name of the other party involved in the acquisition agreement is not provided in this filing.
What is the strategic rationale behind this acquisition for Orgenesis Inc.?
The filing does not detail the strategic reasons or benefits Orgenesis Inc. expects from this acquisition.
When was the material definitive agreement for this acquisition entered into?
The filing states that the report date is July 10, 2024, and it pertains to the entry into a material definitive agreement and completion of an acquisition, but the exact date the agreement was signed is not explicitly stated.
Filing Stats: 838 words · 3 min read · ~3 pages · Grade level 12.3 · Accepted 2024-07-12 14:38:17
Key Financial Figures
- $11,000,000 — ompany (the "Valuation"), not to exceed $11,000,000 (the "Consideration"), less a debt adju
- $10,767,298 — less a debt adjustment relating to the $10,767,298 owed to the Company by Broaden for work
- $3.00 — he Company's common stock at a price of $3.00 per share or 10% above the market price
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex10-1.htm (EX-10.1) — 24KB
- 0001493152-24-027072.txt ( ) — 238KB
- orgs-20240710.xsd (EX-101.SCH) — 3KB
- orgs-20240710_lab.xml (EX-101.LAB) — 33KB
- orgs-20240710_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORGENESIS INC. Date: July 11, 2024 By: /s/ Victor Miller Victor Miller Chief Financial Officer, Treasurer and Secretary